CEPI Expands Partnership with Clover Biopharmaceuticals to Rapidly Advance Development and Manufacture of COVID-19 Vaccine Candidate - Business Wire

CEPI Expands Partnership with Clover Biopharmaceuticals to Rapidly Advance Development and Manufacture of COVID-19 Vaccine Candidate  Business Wire

Comments

Post a Comment

Popular posts from this blog

Gastrointestinal (GI) cancers: After Kate Middleton's diagnosis, here's what abdominal symptoms you should look out ...

Image
rsv in older adults :: Article Creator RSV Vaccine Could Protect High-Risk Adults Under 60, Pfizer Says Topline A late-stage trial of Pfizer's RSV vaccine showed promising results in adults under 60 years old, suggesting the shot could help people as young as 18, the company announced Tuesday, amid an effort to expand the vaccine's availability to more people who are at a higher risk to the potentially lethal infection. Pfizer said the shot—approved for adults age 60 and older—had similar effects in adults over age 18. ... [+] Getty Images Key Facts Pfizer's vaccine, marketed as Abrysvo, resulted in an immune response in adults aged 18 to 59 who are at a higher risk of RSV disease because of underlying medical conditions after a single dose, the company said. The immune response was not worse than the response observed in adults aged 60 and above, whom the Food and Drug Administration approved the vaccine for l...
Read more